Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema

A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema (HAE)

Status

Withdrawn

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01253382

Enrollment

Registered

2010-12-03

Start date

2012-06-01

Completion date

Unknown

Last updated

2021-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Angioedema (HAE)

Brief summary

The primary objective of this study is: * assess the safety and tolerability of ecallantide in paediatric patients for acute attacks of HAE The secondary objectives are: * evaluate the pharmacokinetic profile of ecallantide in paediatric patients treated for acute attacks of HAE * assess the efficacy of ecallantide in paediatric patients treated for moderate to severe acute attacks of HAE

Interventions

BIOLOGICALecallantide

10 - 30mg subcutaneous injection.

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

2 Years to 17 Years

Healthy volunteers

Inclusion criteria

1. Male or female from 2 years of age and prepubertal 2. Physician diagnosis and history of HAE (Type I or II) including laboratory results showing C1-1NH activity below the lower limit of normal or up to 15% above the lower limit of the normal range 3. Present at the site with moderate to severe signs and symptoms of an acute attack of HAE within 8 hours of recognition of the onset of the attack. Spontaneous resolution of the attack must not have begun before the administration of study drug. 4. Must have signed informed consent by parent or caregiver.

Exclusion criteria

1. \<2 years of age or have reached puberty 2. Received treatment with ecallantide within previous 72 hours 3. Received an investigational drug or device, other than ecallantide, within 30 days prior to the screening visit 4. Pharyngeal/laryngeal symptoms 5. Mild attacks including mild edema of the extremities and mild abdominal attacks 6. Are unable or unwilling to give informed consent (parent or caregiver) 7. Any other condition that, in the opinion of the investigator, may compromise the safety or compliance of the patient or would preclude the patient from successful completion of the study

Design outcomes

Primary

Measure	Time frame
safety and tolerability of ecallantide	4 years

Secondary

Measure	Time frame
evaluate the PK profile of ecallantide	4 years
assess the efficacy of ecallantide	4 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026